Last $17.50 USD
Change Today +0.25 / 1.45%
Volume 114.1K
RBGLY On Other Exchanges
Symbol
Exchange
London
OTC US
OTC US
Frankfurt
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

reckitt benckiser-spon adr (RBGLY) Snapshot

Open
$17.34
Previous Close
$17.25
Day High
$17.57
Day Low
$17.25
52 Week High
07/30/14 - $18.23
52 Week Low
08/30/13 - $13.50
Market Cap
63.2B
Average Volume 10 Days
291.4K
EPS TTM
--
Shares Outstanding
3.6B
EX-Date
08/6/14
P/E TM
--
Dividend
$0.41
Dividend Yield
2.63%
Current Stock Chart for RECKITT BENCKISER-SPON ADR (RBGLY)

reckitt benckiser-spon adr (RBGLY) Related Bloomberg News

View More Bloomberg News

reckitt benckiser-spon adr (RBGLY) Related Businessweek News

View More BusinessWeek News

reckitt benckiser-spon adr (RBGLY) Details

Reckitt Benckiser Group plc manufactures and sells health care, hygiene, and home care products. It operates in Europe and North America; Latin America, North Asia, South East Asia and Australia, and New Zealand; Russia and CIS, Middle East, North Africa, Turkey, and Sub-Saharan Africa; RB Pharmaceuticals; and Food segments. The company offers over the counter medications for common ailments, such as pain, fever, cold, flu, sore throat, or heartburn, as well as provides condoms under the Durex, Gaviscon, Mucinex, Nurofen, Scholl, and Strepsils brands. It also offers hygienic products, including disinfectant cleaners, lavatory cleaners, cleaners for household surfaces, and specialty cleaners for cleaning ovens and removing limescale; detergents; pest control products; and skin conditioning products under the Cillit Bang, Clearasil, Dettol, Finish, Harpic, Lysol, Mortein, and Veet brands, as well as under local and multi country brands, such as Brasso, d-Con, Destop, Easy Off, Pif Paf, Pine O Clean, Rid-X, Sagrotan, Sbp, Steradent, St Marc, and Veja brands. In addition, the company offers home care products comprising air care, fabric treatment, and garment care products; water and fabric softeners; laundry detergents; and shoe care products under the Air Wick Calgon Vanish, Woolite, and Spray N Wash brands, as well as under the local and multi country brands, such as Bom Ar, Cherry Blossom, Cobra, Hippo, Jik, Mr Sheen, Mr Min, Napisan, Nugget, O'Cedar, Old English, Oxyclean, Poliflor, Resolve, Robin, and Sole. Further, it provides food products, such as mustard, barbecue sauce, hot sauce, salt, and fried onions under the NoSalt, French’s Mustard, French’s Potato Sticks, French’s Fried Onions, French’s Worcestershire, Frank’s RedHot, and Cattlemen’s brands. Additionally, the company offers SUBOXONE, an opioid medication to treat opioid dependence in an office-based setting. Reckitt Benckiser Group plc was founded in 1823 and is based in Slough, the United Kingdom.

37,100 Employees
Last Reported Date: 04/3/14
Founded in 1823

reckitt benckiser-spon adr (RBGLY) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 4.4M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 2.3M GBP
Compensation as of Fiscal Year 2013.

reckitt benckiser-spon adr (RBGLY) Key Developments

Reckitt Benckiser Group plc Declares Interim Dividend, Payable on September 25, 2014; Reports Unaudited Group Revenue Results for the Second Quarter and Earnings Results for the Six Months Ended June 30, 2014; Provides Earnings Guidance for the Full Year 2014

The Board of Directors of Reckitt Benckiser Group plc declared an interim dividend of 60.0 pence per share compared to 60.0 pence per share paid in 2013. The ex-dividend date will be 6 August 2014 and the dividend will be paid on 25 September 2014 to shareholders on the register at the record date of 8 August 2014. The last date for election for the share alternative to the dividend is 4 September 2014. The company reported unaudited group revenue results for the second quarter and earnings results for the six months ended June 30, 2014. For the quarter, the company reported that net revenue (ex RBP) was £2,125 million, a like for like increase of 4%. Total revenue was £2,299 million compared to £2,477 million a year ago. For the six months, the company reported total revenue of £4,667 million compared to £4,994 million a year ago. Operating profit was £1,059 million compared to £914 million a year ago. Profit before taxation was £1,041 million compared to £898 million a year ago. Profit attributable to owners of the parent was £812 million or 111.1 pence per diluted ordinary share compared to £660 million or 90.4 pence per diluted ordinary share a year ago. Net cash generated from operating activities was £809 million compared to £978 million a year ago. Purchase of property, plant & equipment was £59 million compared to £77 million a year ago. Purchase of intangible assets was £28 million compared to £14 million a year ago. Adjusted profit attributable to owners of the parent was £829 million compared to £864 million a year ago. Net debt as at June 30, 2014 was £2,237 million compared to £2,096 million a year ago. On an adjusted basis, operating profit was down 7% to £1,081 million. On an adjusted basis, diluted EPS declined by 4% to 113.4 pence. The estimated average annual tax rate used for the year to 31 December 2014 is 22% and the adjusted tax rate is 22%. The company is gaining good traction from planned efficiency programmes and expects to have continuing operating margin expansion in the second half (ex RBP).

Reckitt Benckiser Plans Spinoff Of Heroine Addiction Treatment

Reckitt Benckiser Group plc (LSE:RB.) is considering to sell Suboxone. The company plans to spin off its heroin addiction treatment in the next 12 months and said that it was leaning towards spinning off the business rather than a private sale.

RB plc Announces £100 Million Investment in R&D to Build R&D Centre in North of England

RB plc announced it will invest £100 million in its consumer health R&D operations with the creation of a Scientific Excellence to be based in the UK. The new UK centre will become the global technical innovation hub for products such as Nurofen and Strepsils. The decision to locate the new Centre in the UK at the company's Hull site followed a review which considered RB's other R&D centre locations across the globe. Work has already begun on the design and planning aspects of the project and RB expects building work to start early in 2015 with the new Centre of Technical Expertise to be fully operational by early 2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBGLY:US $17.50 USD +0.25

RBGLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
EI du Pont de Nemours & Co $66.11 USD -0.04
Ecolab Inc $114.82 USD +0.43
Mondelez International Inc $36.19 USD -0.10
Novo Nordisk A/S kr259.00 DKK +1.00
PPG Industries Inc $205.86 USD +0.42
View Industry Companies
 

Industry Analysis

RBGLY

Industry Average

Valuation RBGLY Industry Range
Price/Earnings 19.4x
Price/Sales 3.7x
Price/Book 5.8x
Price/Cash Flow 19.2x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECKITT BENCKISER-SPON ADR, please visit www.reckittbenckiser.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.